

Animal Research	SCID beige mice for crizotinib-resistant H2228 xenograft tumor models, nude mice for MGH006 primary explants and MGH045 cells were randomized into groups of 5, 6 or 8 mice with an average tumor volume of ~150 mm ³ and received Crizotinib or ceritinib daily treatments by oral gavage as indicated in each study. Tumor volumes were determined by using caliper measurements and calculated with the formula (Length × Width × Height)/2 [3].
-----------------	--

Solubility Information

Solubility	DMSO: 16 mg/mL (28.67 mM),Sonication is recommended. Ethanol: 3 mg/mL (5.37 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.8 mg/mL (1.43 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7917 mL	8.9583 mL	17.9167 mL
5 mM	0.3583 mL	1.7917 mL	3.5833 mL
10 mM	0.1792 mL	0.8958 mL	1.7917 mL
50 mM	0.0358 mL	0.1792 mL	0.3583 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Hu J, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. *Oncotarget*. 2015 Dec 29;6(42):44643-59.
- Wang J, Xu X, Wang T, et al. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer. *European Journal of Pharmacology*. 2021: 173879.
- Dong S, et al. Ceritinib is a novel triple negative breast cancer therapeutic agent. *Mol Cancer*. 2022 Jun 29;21(1): 138.
- Wang J, Xu X, Wang T, et al. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer. *European Journal of Pharmacology*. 2021: 173879.
- Wu W, Li J, Yin Y, et al. Rutin attenuates ensartinib-induced hepatotoxicity by non-transcriptional regulation of TXNIP. *Cell Biology and Toxicology*. 2024, 40(1): 38.
- Friboulet L, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. *Cancer Discov*. 2014 Jun;4(6):662-673.
- Wang J, Xu X, Wang T, et al. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer[J]. *European Journal of Pharmacology*. 2021: 173879.
- Cen S Y, Lin F, Li X, et al. Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content. *Cell Death Discovery*. 2024, 10(1): 360.
- Li M, Bei Z C, Yuan Y, et al. In-cell bioluminescence resonance energy transfer (BRET)-based assay uncovers ceritinib and CA-074 as SARS-CoV-2 papain-like protease inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2024, 39(1): 2387417.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481